Elite Journal of Laboratory Medicine. Volume 2 issue 3(2024), Pp. 29-38
https://epjournals.com/journals/EJLM

The Impact of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activation on Sickle Cell Anemia: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle Cell Anemia (SCA) is a hereditary blood disorder characterized by the presence of abnormal hemoglobin, leading to chronic hemolytic anemia, vaso-occlusive crises, and multi-organ damage. Oxidative stress plays a crucial role in the pathophysiology of SCA, exacerbating hemolysis and endothelial dysfunction. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of cellular antioxidant defense mechanisms, orchestrating the expression of genes involved in detoxification and antioxidant responses. In recent years, considerable attention has been drawn to the potential therapeutic benefits of Nrf2 activation in mitigating the complications associated with SCA. This review aims to provide a comprehensive overview of the impact of Nrf2 activation on various aspects of SCA pathogenesis and progression, including oxidative stress, inflammation, endothelial dysfunction, vaso-occlusive crises, and organ damage. Additionally, we discuss the molecular mechanisms underlying Nrf2 activation, therapeutic strategies targeting Nrf2, and potential challenges and future directions in the development of Nrf2-based therapies for SCA.

Keywords*: Sickle Cell Anemia, Nrf2, Nuclear Factor Erythroid 2-Related Factor 2, Oxidative Stress, Inflammation, Endothelial Dysfunction, Vaso-occlusive Crises, Antioxidant Defense, Therapeutic Strategies.*

Introduction

Sickle Cell Anemia (SCA) stands as one of the most prevalent inherited blood disorders worldwide, affecting millions of individuals primarily of African descent. It is characterized by a single point mutation in the β-globin gene, leading to the production of abnormal hemoglobin, HbS. This aberrant hemoglobin polymerizes under conditions of deoxygenation, causing red blood cells (RBCs) to assume a sickle shape, triggering a cascade of events including chronic hemolytic

anemia, vaso-occlusive crises, and multi-organ damage. While symptomatic management has improved over the years, SCA continues to pose significant challenges to patients and healthcare providers alike, necessitating novel therapeutic approaches to address its complex pathophysiology. Oxidative stress emerges as a pivotal player in the pathogenesis and progression of SCA. Elevated levels of reactive oxygen species (ROS) contribute to RBC membrane damage, lipid peroxidation, and endothelial dysfunction, exacerbating hemolysis, inflammation, and vaso-occlusive events. Moreover, the chronic inflammatory state inherent to SCA further amplifies oxidative stress, creating a vicious cycle of cellular damage and dysfunction. Given the central role of oxidative stress in SCA-related complications, targeting this pathway has garnered considerable attention as a potential therapeutic strategy.[1-20]

In recent years, nuclear factor erythroid 2-related factor 2 (Nrf2) has emerged as a key regulator of cellular antioxidant defense mechanisms. Nrf2 orchestrates the expression of genes involved in detoxification and antioxidant responses, aiming to restore redox homeostasis and mitigate cellular damage under conditions of oxidative insult. Activation of the Nrf2 pathway represents a promising avenue for ameliorating oxidative stress and related complications in SCA, offering a multifaceted approach to targeting the underlying pathophysiological mechanisms of the disease.

Preclinical studies have provided compelling evidence supporting the therapeutic potential of Nrf2 activation in SCA. Pharmacological agents capable of inducing Nrf2 activation, including small molecule Nrf2 activators and natural antioxidants, have demonstrated efficacy in preclinical models of SCA, improving hemolytic parameters, endothelial function, and vaso-occlusive phenomena. Moreover, genetic manipulation of Nrf2 expression has further elucidated its cytoprotective effects in the context of SCA, highlighting the translational potential of Nrf2-based therapies for clinical application. Despite these promising findings, several challenges remain to be addressed in the development of Nrf2-based therapies for SCA. These include the need for further elucidation of the molecular mechanisms governing Nrf2 activation in SCA, optimization of drug delivery strategies to target specific tissues and organs affected by the disease, and rigorous evaluation of the safety and efficacy of Nrf2-based therapies in clinical trials. Nonetheless, the continued exploration of Nrf2 activation as a therapeutic strategy holds great promise for improving clinical outcomes and quality of life for individuals affected by SCA.[21-35]

Oxidative Stress in Sickle Cell Anemia

Oxidative stress plays a pivotal role in the pathophysiology of Sickle Cell Anemia (SCA), contributing significantly to disease progression and associated complications. The hallmark abnormality in SCA, the presence of hemoglobin S (HbS), triggers a cascade of events leading to chronic hemolytic anemia, vaso-occlusive crises, and end-organ damage. Central to these pathological processes is the generation of reactive oxygen species (ROS) and the inability of antioxidant defense mechanisms to adequately counteract their effects. In individuals with SCA, the abnormal sickle-shaped red blood cells (RBCs) are particularly susceptible to oxidative stress. Hemoglobin S, under conditions of deoxygenation, polymerizes and forms rigid fibers within the RBCs, rendering them more prone to membrane damage. This increased fragility leads to premature RBC destruction, exacerbating hemolysis and perpetuating the release of intracellular

components, including heme and iron, into the circulation. Furthermore, the chronic inflammatory state characteristic of SCA amplifies oxidative stress through various mechanisms. Activated leukocytes, endothelial cells, and platelets release pro-inflammatory cytokines and chemokines, promoting the activation of NADPH oxidase and xanthine oxidase, enzymes involved in ROS generation. In addition, the upregulation of adhesion molecules on the surface of endothelial cells facilitates the adhesion of sickle RBCs to the vascular endothelium, promoting vaso-occlusive events and further exacerbating tissue ischemia and oxidative damage.[36-46]

Oxidative stress in SCA not only affects RBCs but also impacts other cell types and tissues, including endothelial cells, leukocytes, and the vascular endothelium. Endothelial dysfunction, characterized by impaired nitric oxide bioavailability and increased expression of adhesion molecules, contributes to vasoconstriction, thrombosis, and inflammation, perpetuating the cycle of tissue injury and ischemia. Moreover, oxidative stress-induced lipid peroxidation and protein oxidation lead to the generation of cytotoxic by-products, further exacerbating cellular damage and dysfunction. Despite the presence of intrinsic antioxidant defense mechanisms, including enzymes such as superoxide dismutase, catalase, and glutathione peroxidase, their capacity to neutralize ROS is overwhelmed in SCA. The imbalance between ROS production and antioxidant capacity results in oxidative damage to lipids, proteins, and DNA, contributing to the pathogenesis of vaso-occlusive crises, acute chest syndrome, and end-organ damage observed in SCA.[47-50]

Role of Nrf2 in Cellular Antioxidant Defense

The role of nuclear factor erythroid 2-related factor 2 (Nrf2) in cellular antioxidant defense is fundamental to maintaining redox homeostasis and protecting cells from oxidative damage. Nrf2 is a transcription factor that orchestrates the expression of a wide array of genes encoding antioxidant enzymes, phase II detoxification enzymes, and other cytoprotective proteins. Under basal conditions, Nrf2 is sequestered in the cytoplasm by its negative regulator, Kelch-like ECH-associated protein 1 (Keap1), which targets Nrf2 for ubiquitination and subsequent degradation by the proteasome. However, in response to oxidative or electrophilic stress, Keap1 undergoes conformational changes, leading to the release and stabilization of Nrf2, allowing its translocation to the nucleus. Once in the nucleus, Nrf2 heterodimerizes with small Maf proteins and binds to antioxidant response elements (AREs) located in the promoter regions of target genes. This interaction promotes the transcriptional activation of genes encoding antioxidant enzymes such as heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase (GCL), and glutathione S-transferases (GSTs), among others. These enzymes play critical roles in detoxifying reactive oxygen species (ROS), reducing oxidized molecules, and maintaining cellular redox balance.[51-55]

Heme oxygenase-1 (HO-1), a downstream target of Nrf2, catalyzes the degradation of heme into biliverdin, carbon monoxide (CO), and free iron. Biliverdin is subsequently converted into bilirubin, a potent antioxidant that scavenges free radicals and inhibits lipid peroxidation. Carbon monoxide exerts cytoprotective effects by modulating inflammatory responses, inhibiting apoptosis, and promoting vasodilation. Additionally, NQO1 reduces quinones and quinone-imines, thereby preventing the generation of semiquinone radicals and reactive oxygen species.

Moreover, GCL and GSTs play essential roles in the synthesis and metabolism of glutathione, a key intracellular antioxidant involved in ROS scavenging and detoxification. Beyond its direct antioxidant functions, Nrf2 also regulates the expression of genes involved in cellular metabolism, redox regulation, and inflammation. For instance, Nrf2 activation induces the expression of genes encoding enzymes involved in the pentose phosphate pathway (PPP) and the regeneration of reduced glutathione (GSH), thereby providing reducing equivalents and maintaining cellular redox status. Furthermore, Nrf2 activation suppresses the expression of pro-inflammatory cytokines and chemokines, inhibiting the recruitment of immune cells and mitigating inflammatory responses.[56-58]

Impact of Nrf2 Activation on Sickle Cell Anemia

The impact of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) activation on Sickle Cell Anemia (SCA) represents a promising avenue in addressing the oxidative stress-driven pathophysiology of the disease. Nrf2 is a master regulator of cellular antioxidant defense mechanisms, orchestrating the expression of genes involved in detoxification and antioxidant responses. Under conditions of oxidative insult, Nrf2 dissociates from its cytoplasmic inhibitor Keap1 and translocates to the nucleus, where it binds to antioxidant response elements (AREs) in the promoter regions of target genes, leading to the upregulation of antioxidant enzymes and phase II detoxification enzymes. In SCA, the dysregulation of redox homeostasis contributes significantly to disease progression and associated complications. Elevated levels of reactive oxygen species (ROS) and impaired antioxidant defense mechanisms exacerbate oxidative stress, leading to RBC membrane damage, lipid peroxidation, and endothelial dysfunction. Activation of the Nrf2 pathway presents a potential therapeutic strategy for mitigating oxidative stress and related complications in SCA by restoring redox balance and enhancing cellular antioxidant capacity.[59-60]

The therapeutic effects of Nrf2 activation in SCA extend beyond its antioxidant properties. Nrf2 activation has been shown to modulate inflammatory responses, reduce endothelial activation, and enhance vasodilation, thereby addressing multiple facets of SCA pathophysiology. Additionally, Nrf2 activation may exert protective effects on other organs and tissues affected by SCA, including the kidneys, lungs, and brain, by attenuating oxidative damage and inflammation. Despite the promising preclinical data supporting the therapeutic potential of Nrf2 activation in SCA, several challenges remain to be addressed. These include the need for further elucidation of the molecular mechanisms governing Nrf2 activation in SCA, optimization of drug delivery strategies to target specific tissues and organs affected by the disease, and rigorous evaluation of the safety and efficacy of Nrf2-based therapies in clinical trials. Nonetheless, the continued exploration of Nrf2 activation as a therapeutic strategy holds great promise for improving clinical outcomes and quality of life for individuals affected by SCA.[60-61]

Molecular Mechanisms of Nrf2 Activation

The molecular mechanisms underlying Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) activation are intricate and involve a series of tightly regulated processes that culminate in the

transcriptional upregulation of antioxidant and cytoprotective genes. Under basal conditions, Nrf2 is sequestered in the cytoplasm by its negative regulator Kelch-like ECH-associated protein 1 (Keap1), which facilitates its ubiquitination and subsequent proteasomal degradation. However, in response to oxidative stress or electrophilic insults, various signaling pathways are activated, leading to Nrf2 stabilization, nuclear translocation, and activation of its transcriptional program. One of the major pathways involved in Nrf2 activation is the Keap1-Nrf2-ARE signaling axis. Keap1 acts as a sensor for cellular redox status and electrophilic stress, undergoing conformational changes upon modification of its cysteine residues by reactive species. This results in the dissociation of Keap1 from Nrf2, allowing Nrf2 to escape proteasomal degradation. Concurrently, Nrf2 is phosphorylated by various kinases, including protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinases (MAPKs), which enhance its stability and nuclear translocation.[45-50]

Once in the nucleus, Nrf2 forms heterodimers with small Maf proteins and binds to antioxidant response elements (AREs) located in the promoter regions of its target genes. This interaction recruits coactivators such as CREB-binding protein (CBP) and p300, leading to chromatin remodeling and transcriptional activation. Nrf2 regulates the expression of a wide array of genes encoding antioxidant enzymes, phase II detoxification enzymes, and other cytoprotective proteins, including heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione S-transferases (GSTs), and superoxide dismutases (SODs). In addition to the canonical Keap1-Nrf2-ARE pathway, several other mechanisms contribute to Nrf2 activation. These include post-translational modifications of Nrf2, such as phosphorylation, acetylation, and ubiquitination, which modulate its stability, subcellular localization, and transcriptional activity. Furthermore, Nrf2 can be activated by various signaling cascades, including the PI3K/Akt pathway, MAPK pathway, and AMP-activated protein kinase (AMPK) pathway, which converge on Nrf2 to regulate its activity in response to diverse stimuli.[56-60]

Therapeutic Strategies Targeting Nrf2

Therapeutic strategies targeting Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) activation hold significant promise for mitigating oxidative stress and related complications in various diseases, including Sickle Cell Anemia (SCA). Nrf2 serves as a master regulator of cellular antioxidant defense mechanisms, orchestrating the expression of genes involved in detoxification, antioxidant responses, and cytoprotection. Therefore, pharmacological and genetic approaches aimed at enhancing Nrf2 activity represent attractive therapeutic avenues for managing oxidative stress-driven pathologies. Pharmacological agents capable of inducing Nrf2 activation have been extensively investigated as potential therapeutics for diseases associated with oxidative stress, including SCA. Small molecule Nrf2 activators, such as bardoxolone methyl, dimethyl fumarate, and sulforaphane, have shown efficacy in preclinical models by upregulating antioxidant and cytoprotective genes and reducing oxidative damage. Clinical trials evaluating the safety and efficacy of Nrf2 activators in SCA patients are warranted to validate their therapeutic potential.[60-61]

Dietary compounds and botanical extracts rich in antioxidants have been shown to activate Nrf2 and confer protection against oxidative stress-related pathologies. Polyphenols, flavonoids, and sulfur-containing compounds found in fruits, vegetables, and medicinal plants exhibit Nrf2-activating properties and may serve as adjunctive therapies for SCA. Examples include resveratrol, curcumin, quercetin, and epigallocatechin gallate (EGCG), which have demonstrated antioxidant, anti-inflammatory, and vasoprotective effects in preclinical studies. Genetic manipulation of Nrf2 expression or function represents another potential therapeutic strategy for augmenting cellular antioxidant defenses in SCA. Gene therapy approaches aimed at enhancing Nrf2 activity in hematopoietic stem cells (HSCs) or targeting specific tissues affected by the disease may offer long-term benefits for patients. Engineered viral vectors, such as adeno-associated viruses (AAVs) or lentiviral vectors, can deliver Nrf2 or Nrf2-targeting constructs to target cells, leading to sustained Nrf2 activation and cytoprotection.[60]

Given the multifactorial nature of SCA pathophysiology, combination therapies targeting multiple pathways implicated in disease progression may yield synergistic effects and improve therapeutic outcomes. Combining Nrf2 activators with agents targeting inflammation, vaso-occlusion, or hemolytic pathways could offer comprehensive protection against oxidative stress and related complications in SCA. Moreover, personalized treatment approaches tailored to individual patient characteristics and disease phenotypes may enhance therapeutic efficacy and minimize adverse effects. Optimization of drug delivery strategies is essential for ensuring effective targeting and bioavailability of Nrf2 activators to specific tissues and organs affected by SCA. Nanoparticle-based drug delivery systems, liposomal formulations, and targeted drug conjugates can improve the pharmacokinetic properties and tissue distribution of Nrf2 activators, enhancing their therapeutic efficacy while minimizing off-target effects. Furthermore, non-invasive routes of administration, such as oral or inhalation delivery, may enhance patient compliance and facilitate long-term treatment regimens.[61]

Conclusion

The activation of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) represents a promising therapeutic strategy for mitigating oxidative stress and related complications in Sickle Cell Anemia (SCA). Oxidative stress plays a central role in the pathophysiology of SCA, contributing to chronic hemolysis, vaso-occlusive crises, and end-organ damage. Nrf2 serves as a master regulator of cellular antioxidant defense mechanisms, orchestrating the expression of genes involved in detoxification, antioxidant responses, and cytoprotection.

References

1. Mansour AK, Yahia S, El-Ashry R, Alwakeel A, Darwish A, Alrjjal K. Sickle cell disease (SCD). Inherited Hemoglobin Disorders. 2015;35.
2. Tebbi CK. Sickle cell disease, a review. Hemato. 2022;3(2):341-366.
3. Kaur M, Dangi CB, Singh M. An overview on sickle cell disease profile. Asian J Pharm Clin Res. 2013;6(1):25-37.
4. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.

5. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
6. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
7. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
8. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
11. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
12. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
13. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
14. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
15. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
16. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48):e36462.
17. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
18. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
19. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
20. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
21. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
22. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
23. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years

Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
24. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
25. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
26. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
27. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
28. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
29. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
30. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
35. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
36. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
37. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
38. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of

agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
39. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
40. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
41. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
42. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
43. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
44. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
45. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
46. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
47. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
48. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
49. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
50. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
51. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
52. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
53. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
54. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
55. Obeagu EI, Ogunnaya FU, Obeagu GU. Integrated Approaches for Improving Pediatric Health: Addressing Anemia in Malaria Cases. Journal home page: http://www. journalijiar. com.;12(01).
56. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.

57. Conran N, Belcher JD. Inflammation in sickle cell disease. Clinical hemorheology and microcirculation. 2018;68(2-3):263-299.
58. Gbotosho OT, Kapetanaki MG, Kato GJ. The worst things in life are free: the role of free heme in sickle cell disease. Frontiers in immunology. 2021; 11:561917.
59. Wang Q, Zennadi R. The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications. Antioxidants. 2021;10(10):1608.
60. Nash KM, Ahmed S. Nanomedicine in the ROS-mediated pathophysiology: Applications and clinical advances. Nanomedicine: Nanotechnology, Biology and Medicine. 2015;11(8):2033-2040.
61. Ofori-Acquah SF. Sickle cell disease as a vascular disorder. Expert Review of Hematology. 2020;13(6):645-653.